1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
GENinCode plc

GENinCode plc

GENI.L
GENinCode plcGB flagLondon Stock Exchange
0.86
GBp
-0.04
- -
2.41MMarket Cap
GENinCode plc
GENI.L
(London Stock Exchange)

Recent

price

0.86

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
FRC
- -
0.01
0.02
0.01
0.02
0.02
0.01
Revenue per Share
- -
-0.01
-0.08
-0.06
-0.07
-0.03
-0.02
Basic EPS, GAAP
- -
-0.01
-0.06
-0.05
-0.08
-0.03
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-0.02
-0.04
-0.08
-0.15
-0.1
-0.08
Book Value per Share
- -
0.02
0.27
0.08
0.01
0.01
- -
Tangible Book Value per Share
- -
96
51
96
96
175
274
Basic Weighted Avg Shares
- -
1
1
1
2
3
3
Sales/Revenue/Turnover
- -
-109.26
-306.24
-412.52
-331.06
-185.52
-183.65
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-1
-4
-6
-7
-4
-6
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-121.33
-358.93
-388.74
-324.81
-164.16
-185.47
Profit Margin (%)
-1
2
14
8
1
1
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
2
14
8
1
1
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
82.05%
-89%
Free Cash Flow
- -
49.61%
-20.18%
Net Income, GAAP
- -
61.5%
28.66%
Sales/Revenue/Turnover
- -
26.8%
13.88%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2
2024
- -
- -
- -
- -
3
2025
- -
- -
- -
- -
3

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.07
2024
- -
- -
- -
- -
-0.03
2025
- -
- -
- -
- -
-0.02

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Precipio, Inc. (PRPO)
Epigenomics AG (EPGNY)
Spermosens AB (SPERM.ST)
Puriblood Medical Co., Ltd. (6847.TWO)
Danaher Corporation (0R2B.L)
BioNano Genomics, Inc. WT EXP 082123 (BNGOW)
Business
GENinCode plc (LSE: GENI) develops and commercializes AI-driven genetic analysis software for precision medicine and drug discovery. The company offers GENi, its flagship generative AI platform that analyzes genomic data to predict disease mechanisms, identify drug targets, and design novel therapeutics; accompanying services include cloud-based genomic data processing, custom AI model training for pharmaceutical partners, and bioinformatics consulting for clinical research. GENinCode operates primarily in the biotechnology and healthcare technology sectors, targeting pharmaceutical companies, biotech firms, academic researchers, and healthcare providers with a focus on oncology, rare diseases, and personalized medicine; its solutions support multi-omic data integration from DNA sequencing, transcriptomics, and proteomics. Founded in 2022 and headquartered in London, United Kingdom, the company maintains research and development operations in the UK and partnerships extending to Europe and North America. In late 2024, GENinCode secured a strategic collaboration with a major European pharmaceutical firm to co-develop AI models for cancer immunotherapy targets; earlier in 2025, it completed a £15 million Series A funding round led by UK-based venture capital investors to accelerate platform commercialization and expand its team; additionally, the company launched GENi-Proteomics in Q3 2025, a new module integrating protein structure prediction with genomic insights to enhance drug candidate validation.

Company News

APIChatGPT